Yahoo · Jun 9, 2026
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
RV
NASDAQ · RVMDW
Revolution Medicines, Inc. Warrant
Healthcare · Biotechnology
$11.98
Down-$0.48 (-4.01%)
Updated Aug 26, 2026, 1:41 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 154.68M
- P/E ratio
- -15.46
- Dividend yield
- 0.00%
- 52-week range
- $1.53 – $13.00
- Volume
- 6.88K
- Avg. volume
- 28.36K
Price performance
RVMDW price history
1M range · 21 trading sessions · Daily adjusted prices
RVMDW closed at $11.98 after 21 trading sessions, up 35.52% for the selected period.
- Last close
- $11.98
- Period change
- +35.52%
- Period low
- $8.67
- Period high
- $12.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 25, 2026 | $12.69 | $12.869 | $11.98 | $11.98 | 6.88K |
| Aug 24, 2026 | $11.75 | $12.10 | $11.34 | $12.03 | 17.7K |
| Aug 21, 2026 | $12.00 | $12.1337 | $11.60 | $11.80 | 6.47K |
| Aug 20, 2026 | $12.53 | $12.53 | $11.50 | $12.27 | 32.01K |
| Aug 19, 2026 | $13.00 | $13.00 | $12.19 | $12.45 | 25.13K |
| Aug 18, 2026 | $12.085 | $12.62 | $12.03 | $12.585 | 20.3K |
| Aug 17, 2026 | $11.48 | $12.49 | $11.48 | $12.04 | 91.9K |
| Aug 14, 2026 | $11.07 | $11.10 | $10.55 | $11.10 | 11.97K |
| Aug 13, 2026 | $11.11 | $11.38 | $11.02 | $11.10 | 9.94K |
| Aug 12, 2026 | $11.57 | $11.57 | $11.25 | $11.25 | 7.42K |
| Aug 11, 2026 | $11.59 | $11.67 | $11.03 | $11.5799 | 7.89K |
| Aug 10, 2026 | $11.49 | $11.60 | $11.1301 | $11.48 | 14.41K |
| Aug 7, 2026 | $10.60 | $11.50 | $10.32 | $11.50 | 85.13K |
| Aug 6, 2026 | $10.58 | $11.03 | $10.19 | $10.59 | 27.53K |
| Aug 5, 2026 | $10.10 | $10.6292 | $10.00 | $10.25 | 118.92K |
| Aug 4, 2026 | $8.995 | $10.02 | $8.995 | $10.02 | 442.77K |
| Aug 3, 2026 | $9.05 | $9.34 | $8.67 | $8.8399 | 87.93K |
| Jul 31, 2026 | $9.575 | $9.63 | $9.45 | $9.565 | 2.09K |
| Jul 30, 2026 | $8.75 | $9.88 | $8.75 | $9.88 | 13.61K |
| Jul 29, 2026 | $9.08 | $9.08 | $8.37 | $8.67 | 18.12K |
| Jul 28, 2026 | $9.30 | $9.44 | $8.74 | $8.84 | 12.31K |
Latest RVMDW news
The latest Smart Investors Daily articles mentioning RVMDW.
Stock researchCompany · Overview
RVMDW research
Overview
Company profile and research snapshot.
Company profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Jun 9, 2026
Tango Therapeutics stock surges on pancreatic cancer trial data
A combination of vopimetostat and Revolution Medicines' daraxonrasib produced a 92% response rate in patients with advanced pancreatic cancer
Yahoo · Jun 8, 2026
Tango Skyrockets On Eye-Popping Pancreatic Cancer Results
Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines' results in pancreatic cancer.
Yahoo · Jun 8, 2026
Top Midday Gainers
Tango Therapeutics' (TNGX) initial results from a phase 1/2 trial of vopimetostat in combination wit
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
